| Original language | English |
|---|---|
| Pages (from-to) | 1177-1178 |
| Number of pages | 2 |
| Journal | Journal of Neurology, Neurosurgery and Psychiatry |
| Volume | 85 |
| Issue number | 10 |
| DOIs | |
| State | Published - 2014 |
| Externally published | Yes |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 85, No. 10, 2014, p. 1177-1178.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients
AU - Hoepner, Robert
AU - Ahlbrecht, J.
AU - Faissner, S.
AU - Schneider, R.
AU - Dahlhaus, S.
AU - Adams, O.
AU - Raab, P.
AU - Lukas, C.
AU - Chan, A.
AU - Stangel, M.
AU - Gold, R.
N1 - Funding Information: Competing interests RH received research and travel grants from Biogen-Idec and travel grants from Novartis. SF received a travel grant from Biogen-Idec. OA received consulting honoraria from Biogen-Idec. CL has received consulting and speaker’s honoraria from Biogen-Idec, Bayer Schering, Novartis, Sanofi, Genzyme and TEVA, and has received research scientific grant support from Bayer Schering, TEVA and MerckSerono. AC has received personal compensation as a speaker or consultant for Bayer Schering, Biogen-Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva Neuroscience and research support from the German Ministry for Education and Research (BMBF, “German Competence Network Multiple Sclerosis” [KKNMS], CONTROL MS, 01GI0914), Bayer Schering, Biogen Idec, Merck Serono, and Novartis. MS received speakers and consulting honoraria from Bayer Healthcare, Biogen-Idec, Baxter, CSL Behring, Grifols, Merck-Serono, Novartis, Sanofi-Aventis, and Teva. MS is also supported by the Niedersachsen Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony. His institution received research support from Bayer Healthcare, Biogen Idec, Merck-Serono, Novartis, and Teva. RG received speakers and consulting honoraria, scientific grant support from Baxter, Bayer Healthcare, Biogen-Idec, Merck-Serono, Novartis Pharma, Sanofi-Genzyme and Teva Pharma. Funding Information: RH received research and travel grants from Biogen-Idec and travel grants from Novartis. SF received a travel grant from Biogen-Idec. OA received consulting honoraria from Biogen-Idec. CL has received consulting and speaker's honoraria from Biogen-Idec, Bayer Schering, Novartis, Sanofi, Genzyme and TEVA, and has received research scientific grant support from Bayer Schering, TEVA and MerckSerono. AC has received personal compensation as a speaker or consultant for Bayer Schering, Biogen-Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva Neuroscience and research support from the German Ministry for Education and Research (BMBF, "German Competence Network Multiple Sclerosis" [KKNMS], CONTROL MS, 01GI0914), Bayer Schering, Biogen Idec, Merck Serono, and Novartis. MS received speakers and consulting honoraria from Bayer Healthcare, Biogen-Idec, Baxter, CSL Behring, Grifols, Merck-Serono, Novartis, Sanofi-Aventis, and Teva. MS is also supported by the Niedersachsen Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony. His institution received research support from Bayer Healthcare, Biogen Idec, Merck-Serono, Novartis, and Teva. RG received speakers and consulting honoraria, scientific grant support from Baxter, Bayer Healthcare, Biogen-Idec, Merck-Serono, Novartis Pharma, Sanofi-Genzyme and Teva Pharma.
PY - 2014
Y1 - 2014
UR - https://www.scopus.com/pages/publications/84908316980
U2 - 10.1136/jnnp-2014-307582
DO - 10.1136/jnnp-2014-307582
M3 - Letter
C2 - 24700881
AN - SCOPUS:84908316980
SN - 0022-3050
VL - 85
SP - 1177
EP - 1178
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
IS - 10
ER -